Objective To investigate the clinical effect of Marvelonon perimenopausal dysfunctional uterine bleeding. Methods Select the age 40-53 year old appearance ofperimenopausal dysfunctional uterine bleeding of 100 women of childbearing age. The blind were randomly divided into the observation group and the control groupmethod, 50 cases in each group. The observation group and curettage fifth days after the start of Marvelon, begin to take 1 tablets eachtime, every 8 h 1 times, after the cessation of blood every 3 days and decreasing 1/3 dose,to maintain the volume of 1 pieces of/d, a total of 21 days, fifth days after stopping drug withdrawal bleedingbegan to take periodic drug; control group and curettagefifteenth days after the start of oral medroxyprogesterone acetate tablets, 10 mg/d, and even served fifteenth daysafter withdrawal of 10d. withdrawal bleeding began to takeperiodic drug; two of each suit 3 cycle group. Results The observation group after taking the vaginal bleedingcontrol time and complete hemostasis time significantly shorter than the control group, in treatment effect, total effective rate of observation group 90%, contrast group48%, observation group was significantly better than the control group. Conclusion Conclusion Marvelon on perimenopausal dysfunctional uterine bleeding effect is better than the second half cycleof progesterone treatment of perimenopausal dysfunctional uterine bleeding effect, is worth popularizingin clinic.